• 18.12.2019 – 09:00

  Daiichi Sankyo Europe GmbH

  Large Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities

  Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy, showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial[1] · Study reports LIXIANA outcomes from one of the largest observational studies in mainly Caucasian AF ...

  more

• 09.08.2019 – 16:37

  Technische Universität München

  Employees less upset at being replaced by robots than by other people

  TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35645/ NEWS RELEASE Employees less upset at being replaced by robots than by other people Study assesses psychological impact of job losses through ...

  more

• 05.06.2019 – 07:30

  creditshelf

  Study of SMEs: Return-Turbo Digitization - Outperformers rely on IoT, AI and Co.

  Frankfurt (ots) - For 37 percent of medium-sized companies with above-average returns, topics such as the Internet of Things or artificial intelligence are very important in ongoing investment planning. By comparison, only 18 percent of companies with an average or below-average return put these topics at the top of their agenda. These are the results of the ...

  more

• 06.11.2018 – 14:47

  IFCO Systems

  Study: IFCO RPCs extend shelf life of fresh produce by up to 4 days

  Pullach, Germany (ots) - IFCO, the leading global provider of reusable packaging solutions for fresh foods, announced today the results of a study (https://www.ifco.com/000f855f4e852d8f) on the impact of IFCO reusable plastic containers (RPCs) on the shelf life of fresh produce. IFCO RPCs extend the freshness and visual appeal of fresh fruits and vegetables for up to four days compared to single-use packaging. The study ...

  more

• 22.10.2013 – 13:00

  Astellas Pharma Europe Limited

  Medivation and Astellas Announce the Phase 3 PREVAIL Trial of XTANDI?(TM) (Enzalutamide) Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer

  Tokyo And San Francisco (ots/PRNewswire) - - Study will be stopped early and enzalutamide offered to all qualified study participants - 30% Reduction in the Risk of Death, Hazard Ratio = 0.70 ...

  more